Status:

WITHDRAWN

Methotrexate in the Treatment of Axial Spondyloarthritis

Lead Sponsor:

Rheumatism Foundation Hospital

Collaborating Sponsors:

Orion Corporation, Orion Pharma

Conditions:

Spondylarthropathies

Spondylitis, Ankylosing

Eligibility:

All Genders

18-50 years

Phase:

PHASE4

Brief Summary

The goal of this study is to evaluate the efficacy of oral methotrexate for the treatment of active axial spondyloarthritis (early ankylosing spondylitis or spondyloarthritis with sacroiliitis). Effic...

Detailed Description

The established classification criteria for ankylosing spondylitis (AS) rely on the combination of clinical symptoms plus radiographic sacroiliitis of at least grade 2 bilaterally or grade 3 unilatera...

Eligibility Criteria

Inclusion

  • Inflammatory back pain (definition in Calin et al. JAMA 1977;237:2613-4) as the presenting symptom,
  • Positive laboratory test result for HLA-B27,
  • Active sacroiliitis in MRI read by qualified radiologist,
  • Active disease despite treatment with at least two NSAIDs.
  • Active disease is defined as:
  • a score of ≥ 30 mm for morning stiffness (average of 2 scores on a 100 mm visual analog scale \[VAS\] analysing duration and intensity of morning stiffness),
  • scores of ≥ 30 mm VAS for 2 of the following 3 parameters: patient's global assessment of disease activity, back pain and the Bath Ankylosing Spondylitis Functional Index (BASFI).

Exclusion

  • Known hypersensitivity to methotrexate
  • Have received sulfasalazine within 4 weeks prior to the first administration of study agent
  • Using oral corticosteroids on a dose equivalent to ≥10 mg of prednisone/day
  • Any concomitant rheumatic disease other than spondyloarthritis
  • Fibromyalgia
  • Pregnant or breast feeding
  • Have had a serious infection within 1 month
  • Have any known malignancy or have a history of malignancy within the previous 5 years
  • Have current signs or symptoms of severe or uncontrolled renal, hepatic, hematologic, gastrointestinal or pulmonary disease
  • Grade 3 or 4 changes in radiographs of sacroiliac joints (grading of radiographs according to the New York criteria)

Key Trial Info

Start Date :

March 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

Estimated Enrollment :

120 Patients enrolled

Trial Details

Trial ID

NCT00298012

Start Date

March 1 2006

Last Update

January 5 2009

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

Rheumatism Foundation Hospital

Heinola, Finland

2

Helsinki University Central Hospital

Helsinki, Finland

3

Central Finland Central Hospital

Jyväskylä, Finland

4

Kuopio University Hospital

Kuopio, Finland